Typhoid Vi Polysaccharide Vaccine Market Trends and Analysis by Application, Vertical, Region, and Segment Forecast to 2029

 Offering reliable and timely data, this report is a key resource for anyone building or refining their typhoid vi polysaccharide vaccine industry roadmap.

 

 How Large Will The Typhoid Vi Polysaccharide Vaccine Market Be By 2025?
 The typhoid vi polysaccharide vaccine market size has grown rapidly in recent years. It will grow from $5.78 billion in 2024 to $6.71 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to disease prevalence, global health initiatives, traveler vaccination, government immunization efforts, vaccine efficacy and safety.
 
 The typhoid vi polysaccharide vaccine market size is expected to see rapid growth in the next few years. It will grow to $13.09 billion in 2029 at a compound annual growth rate (CAGR) of 18.2%. The growth in the forecast period can be attributed to expanded immunization programs, global health policy focus, epidemiological surveillance, rising demand in travel medicine, environmental and social factors. Major trends in the forecast period include R&D investments, regulatory support, epidemiological studies, public health awareness.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp
 
 What Are Key Factors Driving The Demand In The Global Typhoid Vi Polysaccharide Vaccine Market?
 Rising typhoid prevalence is expected to propel the growth of the typhoid VI polysaccharide vaccine market going forward. Typhoid is an infection caused by the bacteria Salmonella typhi that can be fatal. It usually spreads through contaminated food or drink. Typhoid Vi polysaccharide vaccine is used to immunize adults and children aged 2 and up against typhoid fever caused by Salmonella enterica serovar Typhi, S. Typhi. For instance, in August 2024, according to the data published by the UK Health Security Agency, a UK-based government agency, laboratory-confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland increased from 2021 to 2022, with S. Typhi rising from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. Therefore, the rising typhoid prevalence is driving the growth of the typhoid Vi polysaccharide vaccine market. 
 
 Comparative Analysis Of Leading Typhoid Vi Polysaccharide Vaccine Market Segments
 The typhoid vi polysaccharide vaccinemarket covered in this report is segmented — 
 
 1) By Type: Child; Adult 
 2) By Route Of Administration: Oral; Parenteral 
 3) By Application: Government Institution; Private Sector; Other Applications 
 
 Subsegments:
 1) By Child: Pediatric Formulations; Age-Specific Dosages
 2) By Adult: Standard Adult Formulations; High-Risk Population Formulations
 
 What Are The Upcoming Trends Of Typhoid Vi Polysaccharide Vaccine Market In The Globe?
 Strategic partnerships are a key trend gaining popularity in the typhoid Vi polysaccharide vaccine market. Major companies operating in the typhoid Vi polysaccharide vaccine market are entering into partnerships to strengthen their position in the typhoid Vi polysaccharide market. For instance, in July 2022, The International Vaccine Institute, a South Korea-based international organization focused on infectious diseases of global health importance such as cholera, typhoid, shigella, and salmonella, partnered with Moderna, a US-based biopharmaceutical company. This partnership led to the world’s first affordable oral cholera vaccine and a new-generation typhoid conjugate vaccine.
 
 Who Are The Prominent Players In The Typhoid Vi Polysaccharide Vaccine Business?
 Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited 
 
 View the full typhoid vi polysaccharide vaccine market report here:
 https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report
 
 Which Region Is Expected To Lead The Typhoid Vi Polysaccharide Vaccine Market By 2025?
 Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company